BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2019 4:33:37 AM | Browse: 933 | Download: 931
 |
Received |
|
2018-10-17 02:48 |
|
Peer-Review Started |
|
2018-10-17 08:52 |
|
To Make the First Decision |
|
2018-11-29 07:40 |
|
Return for Revision |
|
2018-11-30 02:42 |
|
Revised |
|
2018-12-31 12:38 |
|
Second Decision |
|
2019-01-16 08:54 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-01-23 17:31 |
|
Articles in Press |
|
2019-01-23 17:31 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-02-21 09:34 |
|
Publish the Manuscript Online |
|
2019-02-22 04:33 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt and François Ghiringhelli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
François Ghiringhelli, MD, Attending Doctor, Doctor, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr |
| Key Words |
Colorectal cancer; Chemotherapy; Irinotecan; Second-line; Aflibercept |
| Core Tip |
This retrospective study suggests that modified FOLFIRI with injection of irinotecan at day 1 and 3 is interesting for patients with previously treated metastatic colorectal cancer. Surprisingly the efficacy of the FOLFIRI3-aflibercept seems superior the FOLFIRI3 alone or in combination with bevacizumab. Prospective randomized trial comparing FOLFIRI-aflibercept to FOLFIRI3-aflibercept in second line are warranted. |
| Publish Date |
2019-02-22 04:33 |
| Citation |
Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85 |
| URL |
https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v10.i2.75 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
